ST Jiaying released its 2026 interim report. Operating revenue was 166 million yuan, down 16.7% year on year. Net loss attributable to the parent was 12.98 million yuan, down 164.6% year on year. Net loss attributable to the parent after deducting non-recurring items was 13.85 million yuan, down 173.7% year on year. Net operating cash flow was negative 54.8 million yuan, down 115.9% year on year. Fully diluted earnings per share was negative 0.0256 yuan. In the second quarter, operating revenue was 42.83 million yuan, down 44.6% year on year. Net loss attributable to the parent was 25.44 million yuan, down 643.6% year on year. Net loss attributable to the parent after deducting non-recurring items was 26.13 million yuan, down 960.1% year on year. Earnings per share was negative 0.0501 yuan. As of the end of the second quarter, total assets were 847 million yuan, down 0.2% from the end of the previous year. Net assets attributable to the parent were 705 million yuan, down 1.8% from the end of the previous year. The company said in the interim report that its main business remains the research, development, production and sale of Chinese patent medicines, covering categories such as throat medicines, cold medicines, orthopaedic medicines, heat-clearing medicines and tonic medicines, and that its leading products continue to hold a certain market share and brand influence.
Guangdong Jiaying Pharmaceutical Co LtdFirst-half net loss widened 164.6% YoY with revenue down 16.7%, indicating deteriorating financial performance.
